GenVec, Inc. (GenVec) is a biopharmaceutical company, engaged in the creation of therapeutics and vaccines. The Company works with companies and organizations, such as Novartis, Merial and the United States Government to support a range of product programs that address the prevention and treatment of a number of human and animal health concerns. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company’s products are developed with its adenovector technology, which uses modified adenoviruses to deliver genes to target cells. It started preclinical programs to develop vaccine candidates for the prevention of RSV and HSV.